Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302

被引：0
|
作者：
Ryan, Charles J.
Londhe, Anil
Molina, Arturo
Smith, Matthew R.
De Bono, Johann Sebastian
Mulders, Peter
Rathkopf, Dana E.
Saad, Fred
Logothetis, Christopher
Fizazi, Karim
Scher, Howard I.
Small, Eric Jay
Matheny, Shannon
Kheoh, Thian San
Griffin, Thomas W.
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Janssen Res & Dev LLC, Raritan, NJ USA
[3] Janssen Res & Dev LLC, Los Angeles, CA USA
[4] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[5] Royal Marsden NHS Fdn Trust, Inst Canc Res, Sutton, Surrey, England
[6] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands
[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[8] Univ Montreal, Montreal, PQ, Canada
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[10] Univ Paris 11, Inst Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5010
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Analysis of the temporal relationship between patient-reported outcomes (PROs) and overall survival (OS) and radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
    Traina, Shana
    Li, Tracy
    Johnson, Kristen
    Ho, Kai Fai
    Molina, Arturo
    Cella, David
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [22] FINAL OVERALL SURVIVAL (OS) ANALYSIS OF COU-AA-302, A RANDOMIZED PHASE 3 STUDY OF ABIRATERONE ACETATE (AA) IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS) WITHOUT PRIOR CHEMOTHERAPY
    Ryan, C. J.
    Smith, M. R.
    Fizazi, K.
    Miller, K.
    Mulders, P.
    Sternberg, C. N.
    Saad, F.
    Griffin, T.
    De Porre, P.
    Park, Y. C.
    Li, J.
    Kheoh, T.
    Naini, V.
    Molina, A.
    Rathkopf, D. E.
    ANNALS OF ONCOLOGY, 2014, 25
  • [23] Prognostic associations of prostate-specific antigen (PSA) decline with survival, radiographic response and progression in chemotherapy-naiive men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide
    Armstrong, A. J.
    Lin, P.
    Higano, C. S.
    Iversen, P.
    Sternberg, C. N.
    Tombal, B.
    Phung, D.
    Parli, T.
    Krivoshik, A.
    Beer, T. M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
    de Bono, Johann S.
    Smith, Matthew R.
    Saad, Fred
    Rathkopf, Dana E.
    Mulders, Peter F. A.
    Small, Eric J.
    Shore, Neal D.
    Fizazi, Karim
    De Porre, Peter
    Kheoh, Thian
    Li, Jinhui
    Todd, Mary B.
    Ryan, Charles J.
    Flaig, Thomas W.
    EUROPEAN UROLOGY, 2017, 71 (04) : 656 - 664
  • [25] PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide
    Gandhy, Shruti U.
    Karzai, Fatima
    Marte, Jennifer L.
    Bilusic, Marijo
    McMahon, Sheri
    Strauss, Julius
    Couvillon, Anna
    Williams, Monique
    Hankin, Amy
    Steinberg, Seth M.
    Figg, William Douglas
    Arlen, Philip M.
    Dahut, William L.
    Gulley, James L.
    Madan, Ravi Amrit
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [26] Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone
    Ryan, Charles J.
    Kheoh, Thian
    Li, Jinhui
    Molina, Arturo
    De Porre, Peter
    Carles, Joan
    Efstathiou, Eleni
    Kantoff, Philip W.
    Mulders, Peter F. A.
    Saad, Fred
    Chi, Kim N.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (01) : 72 - +
  • [27] ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITHOUT PRIOR CHEMOTHERAPY - INTERIM ANALYSIS OF THE COU-AA-302 PHASE 3 TRIAL
    Saad, Fred
    Shore, Neal D.
    Van Poppel, Hendrik
    Rathkopf, Dana
    Smith, Matthew R.
    de Bono, Johann S.
    Logothetis, Christopher
    de Souza, Paul
    Fizazi, Karim
    Mulders, Peter F. A.
    Mainwaring, Paul
    Hainsworth, John D.
    Beer, Tomasz M.
    North, Scott
    Fradet, Yves
    Griffin, Tom
    Kheoh, Thian
    Small, Eric J.
    Scher, Howard I.
    Molina, Arturo
    Ryan, Charles J.
    JOURNAL OF UROLOGY, 2013, 189 (04): : E293 - E293
  • [28] Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy
    Rathkopf, Dana E.
    Smith, Matthew Raymond
    De Bono, Johann Sebastian
    Logothetis, Christopher
    Shore, Neal D.
    De Souza, Paul L.
    Fizazi, Karim
    Mulders, Peter
    Mainwaring, Paul N.
    Hainsworth, John D.
    Beer, Tomasz M.
    North, Scott A.
    Fradet, Yves
    Griffin, Thomas W.
    Park, Youn Choi
    Kheoh, Thian San
    Small, Eric Jay
    Scher, Howard I.
    Molina, Arturo
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [29] Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302)
    Rathkopf, Dana E.
    Smith, Matthew R.
    De Bono, Johann Sebastian
    Logothetis, Christopher
    Shore, Neal
    De Souza, Paul L.
    Fizazi, Karim
    Mulders, Peter
    Mainwaring, Paul N.
    Hainsworth, John D.
    Beer, Tomasz M.
    North, Scott A.
    Fradet, Yves
    Griffin, Thomas W.
    Park, Youn Choi
    Kheoh, Thian San
    Small, Eric Jay
    Scher, Howard I.
    Molina, Arturo
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] Effect of concomitant medication use on outcomes of ties and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).
    Hamilton, Robert James
    Li, Jinhui
    Naini, Vahid
    San Kheoh, Thian
    De Porre, Peter
    Molina, Arturo
    Lelbowitz-Amit, Raya
    De Bono, Johann Sebastian
    Scher, Howard I.
    Ryan, Charles J.
    Chi, Kim N.
    Joshua, Anthony M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345